Khezri Mehrdad, Tavakoli Fatemeh, Mehmandoost Soheil, Sharafi Heidar, Zamani Omid, Bazrafshani Maliheh Sadat, Nasiri Naser, Mirzaei Hossein, Moameri Hossein, Haghdoost Ali Akbar, McKnight Courtney, Des Jarlais Don, Karamouzian Mohammad, Sharifi Hamid
Department of Epidemiology, School of Global Public Health, New York University, New York, NY, USA.
HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Harm Reduct J. 2025 Apr 8;22(1):49. doi: 10.1186/s12954-025-01162-7.
Understanding the hepatitis C virus (HCV) cascade of care (CoC) and factors associated with engagement is crucial for designing interventions for achieving HCV elimination. However, data on engagement in the HCV CoC among people who inject drugs (PWID) in the Middle East and North Africa remains limited. We examined the HCV CoC and factors associated with testing among Iranian PWID.
We recruited PWID in 14 cities using respondent-driven sampling. PWID completed structured interviews capturing measures on socio-demographics, behaviors, and HCV CoC. We examined the self-reported numbers and proportions of individuals who ever tested for HCV, tested positive for HCV antibody, were diagnosed with HCV, initiated HCV treatment, and achieved sustained virologic response (SVR). Multivariable logistic regression models were built to assess factors associated with HCV antibody testing.
Of 2308 PWID, 23.1% had ever received an HCV antibody test, 13.9% received the HCV antibody test in the last year, 3.4% had tested positive for HCV antibodies, and 2.5% had received an HCV diagnosis. Of those diagnosed, 54.4% reported initiating treatment, and 31.6% had achieved SVR. HCV antibody testing was significantly associated with having knowledge about HCV transmission through sharing needle/syringe (adjusted odds ratio [aOR] 8.09; 95% confidence intervals [CI] 5.25, 12.48), living with HIV (aOR 4.15; 1.58, 10.92), no previous history of homelessness (aOR 1.89; 1.31, 2.72), history of arrest/incarceration (aOR 1.83; 1.26, 2.64), history of being diagnosed with any mental health problems (aOR 2.88; 1.79, 4.61), history of non-fatal overdose (aOR 1.51; 1.08, 2.10), receiving needle exchange programs in the last 12 months (aOR 6.20; 3.86, 9.93), opioid agonist treatment in the last six months (aOR 2.10; 1.39, 3.18), and having ever received HBV vaccine (aOR 2.31; 1.59, 3.35).
We found a considerably low engagement in HCV CoC among PWID in Iran. Enhancing access to testing services for PWID, especially those with limited awareness of HCV transmission and those encountering structural challenges, is essential as the initial step in the HCV CoC. This improvement is vital for strengthening HCV elimination efforts in Iran.
了解丙型肝炎病毒(HCV)的照护流程(CoC)以及与参与度相关的因素对于设计实现消除HCV的干预措施至关重要。然而,中东和北非地区注射毒品者(PWID)参与HCV照护流程的数据仍然有限。我们研究了伊朗PWID的HCV照护流程以及与检测相关的因素。
我们在14个城市采用应答者驱动抽样法招募PWID。PWID完成了结构化访谈,收集了社会人口统计学、行为和HCV照护流程方面的信息。我们检查了自我报告的曾接受HCV检测、HCV抗体检测呈阳性、被诊断为HCV、开始HCV治疗并实现持续病毒学应答(SVR)的个体数量和比例。建立多变量逻辑回归模型以评估与HCV抗体检测相关的因素。
在2308名PWID中,23.1%曾接受过HCV抗体检测,13.9%在过去一年接受过HCV抗体检测,3.4%的HCV抗体检测呈阳性,2.5%被诊断为HCV。在那些被诊断的人中,54.4%报告开始治疗,31.6%实现了SVR。HCV抗体检测与了解通过共用针头/注射器传播HCV(调整后的优势比[aOR] 8.09;95%置信区间[CI] 5.25,12.48)、感染艾滋病毒(aOR 4.15;1.58,10.92)、无既往无家可归史(aOR 1.89;1.31,2.72)、有被捕/监禁史(aOR 1.83;1.26,2.64)、有被诊断出任何心理健康问题的病史(aOR 2.88;1.79,4.61)、有非致命过量用药史(aOR 1.51;1.08,2.10)、在过去12个月接受针头交换计划(aOR 6.20;3.86,9.93)、在过去六个月接受阿片类激动剂治疗(aOR 2.10;1.39,3.18)以及曾接种乙肝疫苗(aOR 2.31;1.59,3.35)显著相关。
我们发现伊朗PWID对HCV照护流程的参与度相当低。增加PWID,尤其是那些对HCV传播认识有限以及面临结构挑战的人获得检测服务的机会,作为HCV照护流程的第一步至关重要。这一改进对于加强伊朗的HCV消除工作至关重要。